iBio adds to cardiometabolic and obesity pipeline with AstralBio deal - The Pharma Letter
3 days ago • Google News
iBio, Inc. Common Stock (IBIO)
US$ 5.0534.31%
Price Chart
Key Statistics
Market Cap
$ 8.53M
P/E Ratio
0.65
Revenue (TTM)
$ 375K
Volume
4.88M
52W High
$ 6.89
52W Low
$ 0.64
Dividend Yield
0.00%
Beta
1.02
Technicals
50-Day MA
3.6482
200-Day MA
2.715
52 Week High
6.8908
52 Week Low
0.6358
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases.
Employees
16
Headquarters
San Diego, CA
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg